AB0126 MULTIPARAMETER LINEBLOT IMMUNOASSAY FOR AUTOIMMUNE INFLAMMATORY MYOPATHIES: ADDITION OF cN-1A FOR THE DETECTION OF AUTOANTIBODIES ASSOCIATED WITH INCLUSION BODY MYOSITIS

Background Autoantibodies against cN-1A (Mup44) are primarily used as a biomarker for inclusion body myositis (IBM), they also occur with lower prevalence in systemic lupus erythematosus (SLE) and Sjögren’s Syndrome (SjS). has been included parameter on the multiparameter lineblot Autoimmune Inflammatory Myopathies 16 Ag et (EUROIMMUN), allowing detection of 17 myositis-specific myositis-associated autoantibodies. Objectives The prevalences anti-cN-1A autoantibodies were determined different patient collectives healthy blood donors. Methods A immunoassay containing highly purified, recombinant expressed E.coli was incubated according to instructions. Sera 197 patients IBM, 48 collagenosis (systemic sclerosis, undifferentiated mixed tissue collagenosis), 52 polymyositis/dermatomyositis 75 SLE/SjS screened Additionally, 151 apparently donors well disease control collective comprising sera 20 thyroiditis, 26 neuromuscular disorders, 24 primary biliary cholangitis (PBC), 19 Wegener’s Disease, Coeliac disease, 2 autoimmune liver (ALD) analyzed. Signal intensities automatically evaluated using EUROLineScan software (EUROIMMUN). Results Prevalences 34.5% 10.4% collagenosis, 7.7% polymyositis/dermatomyositis, 13.3% SLE/SjS, 2% donor cohort 4.6% collective. Conclusion addition multiparametric now reduces risk underdiagnosing IBM inflammatory myopathies increases overall diagnostic sensitivity. Disclosure Interests Julia Janz Employee of: EUROIMMUN Medizinische Labordiagnostika AG, Anthonina Ott Marius Richter Thomas Scheper, Wolfgang Schlumberger Meyer AG